Celyad - Blasts get blasted but dose needs definition
Data at ASH on 3 December confirmed that CYAD-01 T-cells can destroy acute myeloid leukaemia (AML) blast (cancer) cells. In eight reported AML...
45 Views
Celyad - Allogeneic trial first dose given
The allogeneic version of NRK CAR T-cell therapy, CYAD-101, is underway with the first patient dosed. The study mirrors the current colorectal...
37 Views
Celyad - Highly encouraging data on dose responses
Celyad has presented an update on its CYAD-01 solid cancer trials with haematological data due in early December. There are strong indications that...
50 Views
Celyad - Allogeneic trial approved in colorectal cancer
The FDA’s sign off on Celyad’s first clinical trial design for its allogeneic NRK CAR T-cell therapy (CYAD-101) is an important milestone. The...
54 Views
Celyad - Developing a sophisticated clinical strategy
Celyad has reached the potentially crucial three billion natural killer receptor (NKR) CAR T-cell dose (CYAD-01) in acute myeloid leukaemia (AML)...
37 Views
No more insights